Specialty Pharma Journal Specialty, Precision & Technology
WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for the treatment of patients with …
Tag Archives: ImmunoGen
June, 2018
May, 2017
-
31 May
ImmunoGen and Sanofi Amend License Agreements Covering All Sanofi Compounds Using ImmunoGen’s Technology
WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of …
February, 2016
-
5 February
ImmunoGen and Merck Partner for Ovarian Cancer Combination Therapy Study
WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced today that they have entered into a clinical research collaboration for the assessment of ImmunoGen’s mirvetuximab soravtansine in combination with …
March, 2015
-
23 March
ImmunoGen Licenses ADC Technology to Takeda for Development of Cancer Drugs
Oncology biotech ImmunoGen, Inc. announced that it has entered into a $440 million antibody-drug conjugate (ADC) licensing deal with Takeda Pharmaceutical Company Limited. Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. Under the deal, ImmunoGen …